Advanced Urothelial Carcinoma
Advertisement
PIVOT-10 expanded on PIVOT-02 by further investigating BEMPEG with nivolumab in cisplatin-ineligible patients.
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
Better quality of life and higher optimism showed to alter the perception people with metastatic disease have about cure.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
A phase 2 study highlights the “encouraging” antitumor activity from futibatinib plus pembrolizumab for patients with ...
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
In patients with pretreated UC, BL-B01D1 demonstrated manageable safety with encouraging antitumor activity.
Enfortumab vedotin plus pembrolizumab showed consistent PFS and OS benefit across all subgroups.
Cohort 2 of TROPHY-U-01 showed that sacituzumab govitecan monotherapy can benefit cisplatin-ineligible patients.
Dr. Sonpavde shares his thoughts on first-line therapy for aUC, including trials like CheckMate 274, AMBASSADOR, and NIAGRA.
Drs. Grande, Nizam continue their conversation on EVITA, including the personalization of treatment to predict toxicity.
Drs. Grande and Nizam discuss the development of criteria for identifying mUC patients ineligible for EV/pembro.
Drs. Gupta and Nizam discuss the findings from the patient-reported outcomes in the EV-302 trial for urothelial carcinoma.
The recorded ORR was 53.5%, and the disease control rate was 74.1%.
Dr. Klümper highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to EV in mUC treatment.
Dr. Grivas offers long-term outcomes from the JAVELIN Bladder 100 study pertaining to specific patient populations.
Dr. Grivas provides an update on relevant clinical trial updates and data readouts pertaining to urothelial carcinoma.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.